Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells

Management of Relapsed and Relapsed/Refractory Multiple Myeloma

(2017) Jacob P. Laubach et al.   Journal of the National Comprehensive Cancer Network

Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines

(2013) J M Eichhorn et al.   Cell Death & Disease

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies

(2012) Shuang Chen et al.   CANCER RESEARCH

Mcl-1 Phosphorylation Defines ABT-737 Resistance That Can Be Overcome by Increased NOXA Expression in Leukemic B cells

(2012) S. Mazumder et al.   CANCER RESEARCH

Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors

(2012) G. J. Gores et al.   GENES & DEVELOPMENT

Up-regulation of Pro-apoptotic Protein Bim and Down-regulation of Anti-apoptotic Protein Mcl-1 Cooperatively Mediate Enhanced Tumor Cell Death Induced by the Combination of ERK Kinase (MEK) Inhibitor and Microtubule Inhibitor

(2012) Takumi Kawabata et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bone Marrow Microenvironment in Multiple Myeloma Progression

(2012) S. Manier et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance

(2012) Andrew J. Kale et al.   JOURNAL OF MEDICINAL CHEMISTRY

Latest advances and current challenges in the treatment of multiple myeloma

(2012) Anuj Mahindra et al.   Nature Reviews Clinical Oncology

Thr 163 Phosphorylation Causes Mcl-1 Stabilization when Degradation Is Independent of the Adjacent GSK3-Targeted Phosphodegron, Promoting Drug Resistance in Cancer

(2012) Shanna K. Nifoussi et al.   PLoS One

Shifting the balance of mitochondrial apoptosis: therapeutic perspectives

(2012) Simone Fulda   Frontiers in Oncology

Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition

(2011) J. Hu et al.   BLOOD

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

(2011) X.-Y. Pei et al.   BLOOD

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

(2011) A. A. Morales et al.   BLOOD

Disruption of IκB Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) Inhibitors

(2011) Yun Dai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

(2011) M Konopleva et al.   LEUKEMIA

Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo

(2010) Y. Dai et al.   BLOOD

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

(2010) Kihyun Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells

(2010) U G Bhat et al.   LEUKEMIA

ARC Synergizes with ABT-737 to Induce Apoptosis in Human Cancer Cells

(2010) U. G. Bhat et al.   MOLECULAR CANCER THERAPEUTICS

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

FoxM1 Is a General Target for Proteasome Inhibitors

(2009) Uppoor G. Bhat et al.   PLoS One

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells

(2008) Y. Dai et al.   BLOOD